Inhaled Nitric Oxide Effective at Treating COVID-19

New York-based Beyond Air, Inc. today announced positive safety and efficacy data from the LungFit® PRO pilot study of high-concentration inhaled nitric oxide (NO) in Community-Acquired Viral Pneumonia (CAVP), including COVID-19.

The LungFit® system produces nitric oxide from ambient air.

The data show that inhaled NO treatment in patients with COVID-19 and other CAVP was well tolerated and safe.

• The trend of shortening of Length of Stay by a factor of 1.8 favors the iNO treatment group.
• Of subjects with unstable saturation during hospitalization, 66.7% of the iNO treatment group reached stable saturation of ≥93% during hospital stay vs. 26.7% in the SST group.
• Duration of oxygen support, including home oxygen support, was significantly shorter for iNO-treated subjects.

“These data from the pilot study of LungFit Pro in CAVP patients show the consistency of improvement demonstrated across important disease-related assessments. We believe these results show that high concentration inhaled NO could be an effective treatment for patients hospitalized with COVID-19,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, in a press release issued on April 25, 2022.

The presentation is available on the Beyond Air website.

Note: This announcement was edited for clarity and manually curated for mobile readership.